Normal Heart Rate While Taking Beta Blockers

Resting Heart Rate on Beta-Blockers: Mechanism, Expected Ranges, and When to Worry

Bailey Reid Gwyn
Interdisciplinary Researcher
2024

Abstract

Beta-adrenergic blockers ("beta blockers") reduce heart rate (HR), blood pressure, and myocardial oxygen demand by antagonizing catecholamine effects at β-receptors. For most adults taking beta blockers, resting HR commonly stabilizes between **50–70 beats per minute (bpm)**; **highly conditioned individuals or those on higher doses may observe resting HR in the high 40s**. This paper outlines the pharmacology behind HR reduction, expected HR ranges, inter-individual variability (drug selectivity, dose, fitness, comorbidities, and co-medications), exercise effects, and clinical thresholds that warrant reassessment. Practical monitoring guidance is provided to support patient-clinician decision-making.

Introduction

Beta blockers (e.g., metoprolol, atenolol, bisoprolol; propranolol, carvedilol) inhibit β-adrenergic signaling, decreasing sinoatrial node firing (negative chronotropy), atrioventricular conduction (negative dromotropy), and contractility (negative inotropy). Cardioselective agents predominantly block **β1** receptors (metoprolol, atenolol, bisoprolol); non-selective agents block **β1/β2** (propranolol) and some add **α1** blockade (carvedilol). The net effect is a **lower resting HR** and a **blunted HR rise during exertion**, reducing cardiac workload in hypertension, ischemic heart disease, certain arrhythmias, and heart failure (with guideline-directed agents).

Background or Context

Expected Resting Heart Rate on Therapy

- Typical range: 50–70 bpm at rest for most adults on stable doses.
- Lower ranges: ~40–50 bpm may occur in athletes or with higher doses/enhanced sensitivity.
- Clinical framing: A lower HR is expected and often therapeutic, provided perfusion is adequate and no bradycardia symptoms are present.

Note: Numeric targets should be individualized to indication (e.g., post-MI, AF rate control, heart failure) and patient tolerance.

Main Argument or Methods

Determinants of Individual HR Response

1 Drug Properties and Dose

- Cardioselectivity: β1-selective agents (metoprolol, atenolol, bisoprolol) primarily slow HR with fewer bronchial/peripheral effects than non-selective drugs.
- Non-selective or mixed blockade: propranolol (β1/β2) and carvedilol (β1/β2 + α1) may have broader hemodynamic effects.
- Dose–response: higher doses generally produce greater HR reduction; titration should be gradual with monitoring.

2 Individual Physiology

- Baseline fitness: trained individuals often begin with low resting HR; beta blockers can lower it further without symptoms.
- Age and conduction system: older adults or those with sick sinus syndrome/AV nodal disease may be more bradycardia-prone.
- Thyroid status: hypothyroidism augments bradycardia risk.

3 Activity and Exercise

- Blunted chronotropic response: peak HR during exertion is lower; perceived exertion may rise sooner.
- Implications: pacing of exercise may need adjustment; formal cardiac rehab or clinician-guided plans can optimize tolerance.

4 Comorbid Conditions

- Heart failure (HFrEF): specific agents (metoprolol succinate, bisoprolol, carvedilol) improve outcomes; careful up-titration and HR/BP surveillance are standard.
- Conduction disease: pre-existing bradyarrhythmias magnify risk.

5 Drug Interactions

- Additive HR-lowering with non-dihydropyridine calcium channel blockers (verapamil, diltiazem), amiodarone, digoxin, ivabradine, and certain antiarrhythmics.

- Other considerations: clonidine co-administration/withdrawal, CYP metabolism interactions (agent-specific).

Analysis or Case Studies

Special Populations

- Athletes: lower baselines are common; focus on symptoms and performance rather than a single HR number.
- Older adults/frailty: start low, go slow; prioritize fall/syncope risk mitigation.
- Asthma/COPD: prefer β1-selective agents; monitor for bronchospasm.
- Diabetes: be aware that beta blockers can mask adrenergic hypoglycemia warnings (e.g., tremor, palpitations); emphasize glucose monitoring.

Discussion

When to Reassess or Seek Care

Immediate clinical contact is prudent if any of the following occur:

- Resting HR < 40 bpm, or a new, progressive decline from baseline.
- Symptoms of bradycardia or hypoperfusion: dizziness, presyncope/syncope, new confusion, extreme fatigue, dyspnea, chest discomfort, or exercise intolerance out of proportion to activity.
- Marked hypotension or new conduction abnormalities (if known).

Asymptomatic resting HR in the high 40s can be acceptable in selected patients (e.g., athletes) under clinician supervision.

Practical Monitoring

1 At Home

- Track resting HR and BP at consistent times (e.g., morning, seated, after 5 minutes of rest).
- Log symptoms, dose changes, and exercise tolerance.
- For arrhythmia indications, note device or wearable alerts if applicable.

2 In Clinic

- Reassess indication-specific goals (e.g., rate control vs. anti-ischemic therapy).
- Review co-medications and electrolytes; consider ECG if symptoms or conduction concerns arise.
- Adjust dosing thoughtfully; avoid abrupt discontinuation (rebound tachycardia/ischemia risk).

Conclusion

On beta-blocker therapy, a **50–70 bpm** resting HR is typical; **high-40s** can be acceptable for some. The clinical priority is **tolerability and perfusion**, not a universal numeric target. Dose, drug selection, conditioning, comorbidities, and co-medications shape the HR response. Proactive monitoring and timely reassessment keep therapy within a safe, effective range.

References

- American Heart Association. *Beta-Blockers*. https://www.heart.org/en/health-topics/heart-attack/treatment-of-a-heart-attack/beta-blockers
- MedlinePlus. *Beta-Blockers*. https://medlineplus.gov/druginfo/meds/a682607.html
- National Institute for Health and Care Excellence (BNF). *Beta-adrenoceptor blocking drugs*. https://bnf.nice.org.uk/

- Merck Manual Consumer Version. *Bradycardia*. https://www.merckmanuals.com/home/heart-and-blood-vessel-disorders/arrhythmias/bradycardia
- Johns Hopkins Medicine. *Bradycardia*. https://www.hopkinsmedicine.org/health/conditions-and-diseases/bradycardia
- Cleveland Clinic. *Beta-Blockers: Types & Side Effects*. https://my.clevelandclinic.org/health/drugs/16426-beta-blockers
- Goldman, L., & Schafer, A. I. (Eds.). (2023). *Goldman-Cecil Medicine* (26th ed.). Elsevier.
- Braunwald, E., Zipes, D. P., Libby, P., & Bonow, R. O. (Eds.). (2019). *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine* (11th ed.). Elsevier.